Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does UROFOLLITROPIN Cause Ovarian hyperstimulation syndrome? 73 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 73 reports of Ovarian hyperstimulation syndrome have been filed in association with UROFOLLITROPIN. This represents 72.3% of all adverse event reports for UROFOLLITROPIN.

73
Reports of Ovarian hyperstimulation syndrome with UROFOLLITROPIN
72.3%
of all UROFOLLITROPIN reports
1
Deaths
66
Hospitalizations

How Dangerous Is Ovarian hyperstimulation syndrome From UROFOLLITROPIN?

Of the 73 reports, 1 (1.4%) resulted in death, 66 (90.4%) required hospitalization.

Is Ovarian hyperstimulation syndrome Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for UROFOLLITROPIN. However, 73 reports have been filed with the FAERS database.

What Other Side Effects Does UROFOLLITROPIN Cause?

Abdominal distension (25) Abdominal pain (20) Ascites (13) Nausea (12) Chest discomfort (10) Dyspnoea (10) Vomiting (10) Oliguria (7) Off label use (5) Pelvic fluid collection (5)

What Other Drugs Cause Ovarian hyperstimulation syndrome?

CHORIOGONADOTROPIN ALFA (1,016) FOLLITROPIN (718) GANIRELIX (672) TRIPTORELIN (356) PROGESTERONE (293) MENOTROPINS (238) LUTROPIN ALFA (194) GONADOTROPHIN, CHORIONIC (173) FOLLITROPIN BETA (163) FOLLITROPIN ALFA (138)

Which UROFOLLITROPIN Alternatives Have Lower Ovarian hyperstimulation syndrome Risk?

UROFOLLITROPIN vs URSODIOL UROFOLLITROPIN vs USTEKINUMAB UROFOLLITROPIN vs USTEKINUMAB-STBA UROFOLLITROPIN vs VADADUSTAT UROFOLLITROPIN vs VALACYCLOVIR

Related Pages

UROFOLLITROPIN Full Profile All Ovarian hyperstimulation syndrome Reports All Drugs Causing Ovarian hyperstimulation syndrome UROFOLLITROPIN Demographics